Mustang Bio (MBIO) Notes Payables (2016 - 2020)

Mustang Bio (MBIO) posted quarterly Notes Payables of $5.0 million for Q2 2020, up 60.0% quarter-over-quarter from $3.1 million in Q1 2020.

Mustang Bio (MBIO) Notes Payables (2016 - 2020) Analysis & Trends

Mustang Bio (MBIO) has reported Notes Payables for 4 consecutive years, with $5.0 million the latest figure, recorded in Q2 2020.

In Q2 2020, Notes Payables changed N/A year-over-year to $5.0 million; the TTM figure through Jun 2020 stood at $5.0 million (changed N/A YoY), while the FY2019 annual figure was $1.2 million, changed N/A from the prior year.
Notes Payables improved to $5.0 million in Q2 2020 per MBIO's latest filing, from $3.1 million in the prior quarter.
Across five years, Notes Payables topped out at $5.0 million in Q2 2020 and bottomed at $28000.0 in Q1 2017.
Historically, Notes Payables has averaged $1.7 million across 4 years, with a median of $1.2 million in 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Mustang Bio	3.90 Mn	3.90 Mn	-

Download Data